-
Continuous glucose monitors, insulin pens, other technology transform diabetes care
New options for collecting timely, comprehensive blood glucose data facilitates real-time tracking of the effects of food, nutrition, and medication. Caitlin Nass, MSN, CRNP, and other panelists explain what real-world changes clinicians and patients living with diabetes experience.
-
Experts debate whether immune or beta cells precipitate progression of type 1 diabetes
Jamie L. Felton, MD, argued that immune cells precipitate disease advancement, while Edward Phelps, PhD, made the case that beta cells are a more influential factor.
Session Coverage
-
Session addresses disparities in access to antiobesity medications
Pharmacoequity describes the goal of ensuring that everyone—regardless of race, ethnicity, or socioeconomic status—has affordable access to life-saving therapies. Panelists including Kristina H. Lewis, MD, MPH, SM, discussed the challenges to attaining pharmacoequity, such as overcoming provider bias.
-
Investigator presents detrimental effects of weight cycling
Weight loss improves diabetes risk factors associated with obesity, yet many patients struggle to maintain weight loss over time. Approximately one in five men and one in four women may experience weight cycling. Heather Caslin, PhD, shared key findings on the harmful effects of these fluctuations.
-
ATTEMPT trial shows kidney, glycemic benefits for SGLT2 inhibitor in adolescents with type 1 diabetes
Jennifer L. Sherr, MD, PhD, and other investigators shared the latest data from the first randomized controlled trial of a sodium-glucose cotransporter protein-2 (SGLT2) inhibitor in adolescents with type 1 diabetes at the 84th Scientific Sessions.
-
TIGHT investigators share lessons learned from evaluating inpatient CGM
Despite a lack of improvement in glycemic management in TIGHT, Guillermo Umpierrez, MD, CDCES, MACP, FACE, said he was optimistic about the future of determining hypoglycemia and hyperglycemia for hospitalized patients with diabetes.
-
FLOW trial demonstrates kidney, cardiovascular benefits of semaglutide in high-risk patients with type 2 diabetes
Investigators presented findings from the first-ever dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist. The trial was stopped early for clear positive efficacy, including slowed progression of kidney disease.
-
LENS results show benefit of fenofibrate in early treatment of diabetic retinopathy
Multiple cardiovascular trials suggested the potential of fenofibrate in treating diabetic retinopathy and informed the hypothesis for LENS, explained Principal Investigator David Preiss, MBChB, MRCP, FRCPath, PhD.
Presenter Profiles
-
Presenter Profile: Molecular Integration of Amino Acid and Fat Metabolism in Health and Metabolic Disease
Phillip J. White, PhD, previews a presentation at the 84th Scientific Sessions. Attendees in Orlando can watch the session in-person Monday, June 24, at 8:00 a.m. ET, and select recordings will be available on the meeting’s virtual platform after the live presentations.
-
Presenter Profile: Diabetes Genetic Convergence—Shared Networks of Rare and Common Variants
Yan Li, PhD, previews a presentation at the 84th Scientific Sessions. Attendees in Orlando can watch the session in-person Monday, June 24, at 3:15 p.m. ET, and select recordings will be available on the meeting’s virtual platform after the live presentations.
-
Presenter Profile: Improving Culture of Quality in Pediatric Centers—Lessons from the Type 1 Diabetes Exchange Quality Improvement Collaborative
Anna Cymbaluk, MD, previews a presentation at the 84th Scientific Sessions. Attendees in Orlando can watch the session in-person Monday, June 24, at 3:15 p.m. ET, and select recordings will be available on the meeting’s virtual platform after the live presentations.